Sartorius Embeds AI in Bioprocess Strategy

- Sartorius is expanding its collaboration with NVIDIA, which began in 2020, to create and commercialize foundational AI models based on Sartorius' datasets. The partnership focuses on using the NVIDIA Clara suite to develop predictive models of stem cell-derived organoids, aiming to replace animal models in drug discovery, and to simulate bioprocesses for innovative therapies. - The company's AI research is also anchored by its role as a shareholder in the German Research Center for Artificial Intelligence (DFKI), which started in September 2020. The two entities operate a joint Sartorius AI Lab (SAIL) to develop deep learning algorithms for image recognition of cells and to simulate and optimize biopharmaceutical production processes. - A key application of this strategy is the development of bioprocess digital twins, which are virtual models of an entire process chain that integrate real-time data from systems like LIMS and MES. These models are used to predict critical quality attributes (CQAs), reduce out-of-spec events, and shorten technology transfer timelines in GMP manufacturing. - In cell line development for biologics, the company uses AI with its high-throughput CellCelector™ automation platform to analyze imaging and fluorescence data. This allows for the prediction of clones that will reliably produce high titers, reducing development timelines and the risk of failure. - For viral vector manufacturing, AI and machine learning are being applied to optimize the coding sequences of vector components to improve stability and efficacy. These techniques are also used to predict the genotoxicity of viral vectors and to help analyze empty-to-full capsid ratios during production. - Sartorius is deploying its AI-driven technology through CDMO partnerships, such as with Mycenax Biotech, which has adopted the 4Cell® CHO cell line development platform. This platform uses AI-based screening to identify high-producer clones in the early stages of culture, aiming to establish a research cell bank in just nine weeks. - The company's focus on AI is part of a broader industry shift toward "Biomanufacturing 4.0," which uses data-driven approaches and automation to address challenges like data fragmentation and lack of standardization in manufacturing. This trend sees the integration of robotics, AI, and Process Analytical Technologies (PAT) directly into manufacturing floors for real-time monitoring and control. - This strategic investment in AI is supported by strong financial performance, particularly in the Bioprocess Solutions division. For 2026, the Sartorius Group forecasts sales revenue growth of 5% to 9% in constant currencies with an underlying EBITDA margin slightly above 30%.